Detalles de la búsqueda
1.
ChAdOx1 nCoV-19 (AZD1222) vaccine-induced Fc receptor binding tracks with differential susceptibility to COVID-19.
Nat Immunol
; 24(7): 1161-1172, 2023 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-37322179
2.
Efficacy of the ChAdOx1 nCoV-19 Covid-19 Vaccine against the B.1.351 Variant.
N Engl J Med
; 384(20): 1885-1898, 2021 05 20.
Artículo
en Inglés
| MEDLINE | ID: mdl-33725432
3.
T-cell responses induced by ChAdOx1 nCoV-19 (AZD1222) vaccine to wild-type severe acute respiratory syndrome coronavirus 2 among people with and without HIV in South Africa.
AIDS
; 37(1): 105-112, 2023 01 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-36476455
4.
Durability of ChAdOx1 nCoV-19 (AZD1222) vaccine and hybrid humoral immunity against variants including omicron BA.1 and BA.4 6 months after vaccination (COV005): a post-hoc analysis of a randomised, phase 1b-2a trial.
Lancet Infect Dis
; 23(3): 295-306, 2023 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-36273491
5.
Efficacy of primary series AZD1222 (ChAdOx1 nCoV-19) vaccination against SARS-CoV-2 variants of concern: Final analysis of a randomized, placebo-controlled, phase 1b/2 study in South African adults (COV005).
Vaccine
; 41(23): 3486-3492, 2023 05 26.
Artículo
en Inglés
| MEDLINE | ID: mdl-37149443
6.
Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 in people living with and without HIV in South Africa: an interim analysis of a randomised, double-blind, placebo-controlled, phase 1B/2A trial.
Lancet HIV
; 8(9): e568-e580, 2021 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-34416193
Resultados
1 -
6
de 6
1
Próxima >
>>